<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Four consecutive children with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) underwent matched allogeneic bone marrow transplantation (BMT) </plain></SENT>
<SENT sid="1" pm="."><plain>Ages ranged from 3.2 to 6.3 years </plain></SENT>
<SENT sid="2" pm="."><plain>Diagnosis was assessed according to FAB classification: <z:hpo ids='HP_0005505'>refractory anemia</z:hpo>-RA (n = 1), RA with excess of blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>) (n = 1), and juvenile <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">JCML</z:e>) (n = 2) </plain></SENT>
<SENT sid="3" pm="."><plain>Initial treatment included transfusions for <z:hpo ids='HP_0000001'>all</z:hpo> of them, splenectomy (n = 2) and chemotherapy (n = 1) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients were <z:hpo ids='HP_0000001'>all</z:hpo> prepared with <z:chebi fb="0" ids="28901">busulfan</z:chebi> 21 mg/kg (480 mg/m2), <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> 24,000 mg/m2, melphalan 140 mg/m2 </plain></SENT>
<SENT sid="5" pm="."><plain><z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">Graft-versus-host disease</z:e> (GVHD) prophylaxis associated <z:chebi fb="0" ids="4031">cyclosporine</z:chebi>-<z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Engraftment was prompt and complete in <z:hpo ids='HP_0000001'>all</z:hpo> children </plain></SENT>
<SENT sid="7" pm="."><plain>Toxicity included severe mucositis (n = 3), moderate <z:e sem="disease" ids="C0948441" disease_type="Disease or Syndrome" abbrv="VOD">veno-occlusive disease</z:e> (n = 2), <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD (n = 3), <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD (n = 1) </plain></SENT>
<SENT sid="8" pm="."><plain>Sequelae have not yet been seen </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients are alive and disease-free with a follow-up ranging from 7 to 35 months, with a Karnofsky score of 90-100% </plain></SENT>
<SENT sid="10" pm="."><plain>Combined busulphan conditioning can offer an alternative to total body irradiation-based regimens in order to avoid late side-effects in children </plain></SENT>
</text></document>